Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours-Reference-Cited by-同舟云学术

Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours

Published:2023-11 Issue: Volume: Page:
ISSN:0168-8278
Container-title:Journal of Hepatology
language:en
Short-container-title:Journal of Hepatology

Author:

Celsa Ciro^ORCID,Cabibbo Giuseppe^ORCID,Fulgenzi Claudia A.M.,Scheiner Bernhard^ORCID,D’Alessio Antonio,Manfredi Giulia F.^ORCID,Nishida Naoshi^ORCID,Ang Celina,Marron Thomas U.,Saeed Anwaar,Wietharn Brooke^ORCID,Pinter Matthias^ORCID,Cheon Jaekyung^ORCID,Huang Yi-Hsiang^ORCID,Lee Pei-Chang,Phen Samuel^ORCID,Gampa Anuhya,Pillai Anjana,Vivaldi Caterina^ORCID,Salani Francesca^ORCID,Masi Gianluca^ORCID,Roehlen Natascha^ORCID,Thimme Robert,Vogel Arndt^ORCID,Schönlein Martin^ORCID,von Felden Johann,Schulze Kornelius,Wege Henning,Galle Peter R.^ORCID,Kudo Masatoshi^ORCID,Rimassa Lorenza^ORCID,Singal Amit G.^ORCID,El Tomb Paul,Ulahannan Susanna,Parisi Alessandro^ORCID,Chon Hong Jae^ORCID,Hsu Wei-Fan^ORCID,Stefanini Bernardo^ORCID,Verzoni Elena,Giusti Raffaele^ORCID,Veccia Antonello,Catino Annamaria^ORCID,Aprile Giuseppe,Guglielmini Pamela Francesca,Di Napoli Marilena,Ermacora Paola,Antonuzzo Lorenzo,Rossi Ernesto^ORCID,Verderame Francesco^ORCID,Zustovich Fable,Ficorella Corrado,Di Pietro Francesca Romana,Battelli Nicola,Negrini Giorgia,Grossi Francesco^ORCID,Bordonaro Roberto,Pipitone Stefania,Banzi Maria,Ricciardi Serena,Laera Letizia,Russo Antonio,De Giorgi Ugo,Cavanna Luigi^ORCID,Sorarù Mariella^ORCID,Montesarchio Vincenzo,Bordi Paola,Brunetti Leonardo^ORCID,Pinto Carmine^ORCID,Bersanelli Melissa,Cammà Calogero,Cortellini Alessio,Pinato David J.^ORCID

Publisher

Elsevier BV

Subject

Hepatology

Reference36 articles.

1. Improved survival with ipilimumab in patients with metastatic melanoma;Hodi;N Engl J Med,2010

2. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma;Finn;N Engl J Med,2020

3. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs.. sorafenib for unresectable hepatocellular carcinoma;Cheng;J Hepatol,2022

4. Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study;Qin;Lancet,2023

5. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways;Fife;Immunol Rev,2008